SOURCE: Cutting Edge Information

July 03, 2008 09:39 ET

Oncology Market to Grow to $85 Billion by 2013, According to New Therapeutic Study by Cutting Edge Information

RESEARCH TRIANGLE PARK, NC--(Marketwire - July 3, 2008) - The oncology market will grow from $57 billion in 2007 to more than $85 billion in 2013, according to a new report by Cutting Edge Information.

Along the way, many drugs are expected to be big winners for their companies: a total of 21 oncology and adjunct drugs are anticipated to reach blockbuster status by 2012.

The new study, "The Oncology Market Forecast to 2013," provides a detailed look at the entire oncology market -- including drug class breakdowns, profiles of top companies, and current and future blockbusters. A report brochure is available for download here: http://www.cuttingedgeinfo.com/oncology/TA220_Download.asp

"The cancer market is projected to increase dramatically, and companies across the industry are scrambling to increase their share in this market," said Eric Bolesh, Research Team Leader at Cutting Edge Information.

In some cases, firms are seeking to replace oncology sales that will be lost to patent expirations in 2010 or 2011. In other cases, they're hoping a healthy oncology portfolio will replace sales lost in other therapeutic areas.

"In both of these situations," Bolesh said, "newcomers face tremendous competition from established players. Much oncology market share is heavily concentrated in only a few companies."

The 420+ page report examines more than 130 drugs and provides market analysis on multiple levels, including:

Individual Drug Profiles - Drug profiles include information about drugs' competitive, strategic and market growth positions based on the following information:

--  Past financial performance and future prospects
--  Patent/litigation information
--  Development progress across all indications
--  Market-changing events, including competitor patent expirations and
    trial results
    

Oncology Indication Market Outlook - Detailed outlooks for the breast, colorectal, lung and prostate cancer and leukemia markets. This outlook is based on the following included information:

--  Epidemiology
--  Drug sales & forecasts
--  Pipeline summaries
--  Market events
--  Marketed products
    

Company Profiles - Oncology breakdowns for 14 pharmaceutical and biotechnology companies. These firms either have established oncology franchises or exciting development pipelines for new cancer compounds. Research includes:


--  Market share and oncology revenue
--  Competitive and strategic positioning in the oncology market
--  Company performance -- strengths, weaknesses and competitive threats
--  Drug-by-drug examination of company's oncology pipeline
    

Contact Information